Literature DB >> 28040789

Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.

Filip Rázga1, Veronika Némethová2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28040789      PMCID： PMC5210257          DOI： 10.3324/haematol.2016.157065

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.

Authors:  Eva Barragán; María Carmen Chillón; Remedios Castelló-Cros; Nerea Marcotegui; María Isabel Prieto; Montserrat Hoyos; Raffaella Pippa; Marta Llop; Amaia Etxabe; José Cervera; Gabriela Rodríguez; Ismael Buño; José Rifón; Jorge Sierra; Marcos González; María J Calasanz; Miguel A Sanz; María D Odero
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

3.  The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Authors:  L N Eadie; P Dang; V A Saunders; D T Yeung; M P Osborn; A P Grigg; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

4.  MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.

Authors:  Velizar Shivarov; Anna Dolnik; Katharina M Lang; Jan Krönke; Florian Kuchenbauer; Peter Paschka; Verena I Gaidzik; Hartmut Döhner; Richard F Schlenk; Konstanze Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

Review 5.  OCT1 and imatinib transport in CML: is it clinically relevant?

Authors:  D B Watkins; T P Hughes; D L White
Journal:  Leukemia       Date:  2015-07-09       Impact factor: 11.528

6.  Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

Authors:  Zdenek Racil; Filip Razga; Katerina Machova Polakova; Lucie Buresova; Vaclava Polivkova; Dana Dvorakova; Daniela Zackova; Hana Klamova; Petr Cetkovsky; Jiri Mayer
Journal:  Leuk Lymphoma       Date:  2010-12-06

7.  The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Authors:  Athina Giannoudis; Lihui Wang; Andrea L Jorgensen; George Xinarianos; Andrea Davies; Sudeep Pushpakom; Triantafilos Liloglou; Jieying-Eunice Zhang; Gemma Austin; Tessa L Holyoake; Letizia Foroni; Panagiotis D Kottaridis; Martin C Müller; Munir Pirmohamed; Richard E Clark
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

Review 8.  miRNAs as Biomarkers in Chronic Myelogenous Leukemia.

Authors:  Kasuen Kotagama; Yung Chang; Marco Mangone
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

Review 9.  Clinical significance of microRNAs in chronic and acute human leukemia.

Authors:  Chien-Hung Yeh; Ramona Moles; Christophe Nicot
Journal:  Mol Cancer       Date:  2016-05-14       Impact factor: 27.401

10.  The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.

Authors:  Zdenek Racil; Filip Razga; Lucie Buresova; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Shira Timilsina; Petr Cetkovsky; Jiri Mayer
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.